We spend considerable time discussing the challenges facing medicine, appropriately so. Administrative burden, declining reimbursement, workforce pressures, prior authorization, and burnout are real and affect our ability to care for our patients. But amid these challenges, something remarkable is happening. The boundaries of what we can offer our patients are changing before our eyes.
Explore This Issue
November 2026What an extraordinary time to be an otolaryngologist.
Consider hearing loss. For generations, we have helped patients compensate for lost auditory function through hearing aids and cochlear implants. Today, gene therapy is beginning to offer something fundamentally different: the possibility of restoring biologic hearing in children with specific forms of genetic deafness.
In rhinology, our understanding of chronic inflammatory disease has similarly transformed. We have moved beyond treating the consequences of inflammation with repeated courses of medications and surgery toward targeting the underlying immunologic pathways with biologic therapies. Increasingly, the question is not simply whether to operate, but how surgery and biologic therapy should be selected, sequenced, or combined for an individual patient.
And in cancer care, another boundary is being crossed. This summer, a Phase 3 trial of an individualized mRNA neoantigen therapy for melanoma demonstrated improvement in recurrence-free survival. Imagine what that represents: identifying the mutations within an individual patient’s tumor and creating a therapy designed to teach that patient’s immune system to recognize and attack their cancer.
These advances should fill us with optimism. But they should also challenge us.
Scientific discovery does not automatically translate into better patient care. We have an extraordinary opportunity and responsibility to shape what comes next.
As leaders, we must create environments of continuous learning where physicians can understand rapidly evolving therapeutic options. We must protect scientific curiosity and create space for discovery, mentorship, and investigation even amid growing pressures for clinical productivity. Today’s transformative treatments exist because someone was given the opportunity to ask a question whose answer was not yet known.
Our organizational structures must evolve with our science. We cannot celebrate multidisciplinary precision medicine while continuing to deliver care in rigid silos. The multidisciplinary team of the future cannot simply be a conference. It must increasingly become the architecture through which care is delivered, bringing together surgeons, physicians, scientists, audiologists, geneticists, pathologists, and other professionals around the needs of an individual patient.
Perhaps most importantly, greater therapeutic choice creates an even greater need for communication. Surgery versus biologic therapy. Cochlear implantation versus gene therapy. Conventional oncologic treatment versus molecularly targeted or immune therapy. These decisions require discussions not only about efficacy, but also uncertainty, durability, risk, quality of life, cost, and what matters most to each patient.
As our therapeutic capabilities become more sophisticated, our need for human connection becomes greater, not less.
The residents we train today will practice a form of otolaryngology we cannot fully imagine. Our responsibility is not simply to prepare them for the medicine we practice today, but to create the culture, systems, and curiosity that will allow them to shape the medicine of tomorrow.
The future of otolaryngology is not simply happening to us. We have the extraordinary opportunity to shape what comes next.
What an amazing time to be an otolaryngologist.
—Robin

Leave a Reply